ADEQUAN JOINS FORCES WITH THE ARABIAN HORSE ASSOCIATION AS THE “OFFICIAL JOINT THERAPY SPONSOR”

ADEQUAN JOINS FORCES WITH THE ARABIAN HORSE ASSOCIATION

AS THE “OFFICIAL JOINT THERAPY SPONSOR”

The Arabian Horse Association announced that one of the nation’s leaders in the fight against degenerative joint disease in horses, the veterinarian-trusted name of Adequan® (polysulfated glycosaminoglycan) is now a corporate sponsor and the “Official Joint Therapy Sponsor of AHA.”

Luitpold Pharmaceuticals, manufacturer of the flagship equine health product, Adequan®, will be represented at national shows and at the AHA convention in Reno in November during the general session. “Adequan is certainly an excellent fit for AHA,” said Cory H. Soltau, DVM. “Adequan has a long and safe track record for strong efficacy in the treatment of equine joints.”

Lance Walters, AHA president said, “We’re proud to have this new partnership with Luitpold Pharmaceuticals. The Adequan brand has a tremendously positive reputation – a terrific match for our 100-year-old breed association. From distance and racing to reining and the show ring, Arabian horse owners have long understood the usefulness of this fine product. We welcome Luitpold to the AHA family.”

Allyn Mann, Senior Manager of the Animal Health Division at Luitpold, said, “We continue to share the vision of Arabian Horse Association to promote excellence in their breed and the welfare of the horses. With Adequan® i.m., the only FDA-approved disease modifying joint disease treatment, Arabian horse owners can help keep their horses performing at the top of their game,” Mann continued. “We appreciate that AHA members have shown confidence in our brand, our product and our results. They know from experience that we understand the needs of performance horses and that we support the devoted equestrians and horses throughout the industry.”

Due to the rigors of competition, many performance horses suffer from joint disease. Adequan® is designed to help treat the underlying cause of the problem and break the cycle of damage, while reducing pain and inflammation.

To learn more about the causes, effects and treatments for equine degenerative joint disease, Adequan® offers a free educational CD or on-line video. To request this free educational video, call 1-800-974-9247, or visit www.adequan.com.

###

There are no known contraindications to the use of intramuscular polysulfated glycosaminoglycan or PSGAG in horses. Studies have not been conducted to establish safety in breeding horses. Go to www.adequan.com or call 800-974-9247 for full prescribing information. Adequan® i.m. is a registered trademark of Luitpold Pharmaceuticals, Inc.

AHA is a major equine association serving 37,000 members across North America. It registers and maintains a database of more than one million Arabian, Half-Arabian and Anglo-Arabian horses and administers approximately $3 million in annual prize money. AHA produces championship events, recognizes close to 600 Arabian horse shows and distance rides and provides activities and programs that promote breeding and ownership. For information about Arabian, Half-Arabian and Anglo-Arabian horses, call 303-696-4500, e-mail info@ArabianHorses.org or visit ArabianHorses.org